$20 million financing led by BRV Capital Management includes new investors Lockheed Martin Ventures, Applied Ventures, Lam Capital, GK Goh, and the British Business Bank, with participation from existing investors Octopus Ventures, Foresight Group, and OTIF Ventures
OTIF Ventures portfolio company Caristo Diagnostics has received FDA De Novo authorisation for CaRi-Heart®, the first technology authorised in the US to measure coronary inflammation from routine cardiac CT scans.
Oxford Quantum Circuits (OQC) has closed an oversubscribed £260m ($350m) Series C, the largest private funding round ever raised by a quantum computing company in Europe. OTIF Ventures is proud to have participated as a continuing investor in this milestone raise.
Marking an exciting new chapter, OTIF Ventures builds on a strong EIS track record with one of its most attractive investment pipelines to date.
OTIF Ventures welcomed portfolio company leaders, investors and guests to its recent London Showcase, formally introducing the firm’s new trading name alongside a selection of high-potential prospective investments for Tranche 15